Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 366

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

Open access
Khanani, Arshad M, Patel, Sunil S, Staurenghi, Giovanni, Tadayoni, Ramin, Danzig, Carl J, Eichenbaum, David A, Hsu, Jason, Wykoff, Charles C, Heier, Jeffrey S, Lally, David R, Monés, Jordi, Nielsen, Jared S, Sheth, Veeral S, Kaiser, Peter K, Clark, Julie, Zhu, Liansheng, Patel, Hersh, Tang, Justin, Desai, Dhaval, Jaffe, Glenn J, Alezzandrini, Arturo, Francone, Anibal Andres, Bafalluy, Joaquín, Bainttein, Silvina, Luna Pinto, Jose, Saravia, Mario, Vidosevich, Matko, Zeolite, Carlos, Furno Sola, Federico, Chang, Andrew, Cornish, Elisa Eleanor Guida, Nguyen, Thanh, Findl, Oliver, Haas, Anton, Kralinger, Martina, Sacu, Stefan, Postelmans, Laurence Dominique, Farah, Michel, Maia, Mauricio, Nehemy, Marcio, Ali, Fareed, Brent, Michael, Dollin, Michael, Gonder, John, Kherani, Amin, Merkur, Andrew, Tuli, Raman, Lopera, Monica Marie, Rodriguez, Francisco, Bradvica, Mario, Ernest, Jan, Kalijurand, Kuldar, Noor, Kai, Cohen, Yves, Creuzot-Garcher, Catherine, De Bats, Flore, Devin, François, Français-Maury, Catherine, Kodjikian, Laurent, Korobelnik, Jean François, Le Mer, Yannick, Quaranta El Maftouhi, Maddalena, Razavi, Sam, Souied, Eric, Tadayoni, Ramin, Weber, Michel, Eter, Nicole, Feltgen, Nicolas, Grisanti, Salvatore, Walter, Peter, Liegl, Raffael, Lorenz, Katrin, Spital, Georg, Priglinger, Siegfried, Spitzer, Martin, Volker, Michael, Krohne, Tim, Jochmann, Claudia, Lohmann, Chris Patrick, Framme, Carsten, Kerenyi, Agnes, Papp, Andras, Seres, Andras, Toth-Molnar, Edit, Tsorbatzoglou, Alexis, Vajas, Atilla, Varsanyi, Balázs, Vogt, Gabor, Bar, Asaf, Eting, Eva, Hauser, David, Levy, Jamie, Mathalone, Nurit, Morori-Katz, Haia, Rosenblatt, Irit, Soudry-Zayit, Shiri, Trivizky, Omert, Bandello, Francesco, Ciardella, Antonio Pasquale, Figus, Michele, Giansanti, Fabrizio, Lanzetta, Paolo, Mariotti, Cesare, Mastropasqua, Leonardo, Midena, Edoardo, Parmeggiani, Francesco, Ricci, Federico, Simonelli, Francesca, Staurenghi, Giovanni, Viola, Francesco, Varano, Monica, Laganovska, Guna, Cisiecki, Sławomir, Jedrzejewski, Wojciech, Kaluzny, Jakub, Misiuk-Hojło, Marta, Abengoechea, Santiago, Iribarren, Javier Araiz, Ascaso, Franciso Javier, Cubero, Juan Manuel, Gallego-Pinazo, Roberto, Gomez-Ulla De Irazazabal, Francisco, Mestre, Ignasi Jürgens, Mones I Carilla, Jordi Manel, Montero Moreno, Javier, María Ruiz Moreno, José, Sararols Ramsay, Laura, Garcia Layana, Alfredo, Downey, Louise, Abraham, Prema, Alfaro, Daniel Virgil, Bagheri, Nika, Barbazetto, Irene, Benevento, Joseph, Bernstein, Paul, Bertolucci, George, Bhavsar, Abdhish, Bridges, William, Brooks, Jr, Harold Logan, Brown, Jamin, Brucker, Alexander, Calvo, Charles M., Capone, Antonio, Carlson, John, Chan, Clement, Chang, Emmanuel, Chan-Kai, Brian, Chaudhry, Nauman, Chen, Sanford, Csaky, Karl, Cummings, Howard, Danzig, Carl, Dessouki, Amr, Dyer, David, Eaton, Alexander, Eichenbaum, David, Faber, David, Feldman, Robert, Finnen, Neil, Freeman, William, Frenkel, Ronald, Gonzales, Christine, Gonzalez, Victor, Gross, John, Gupta, Sunil, Hall, Edward, Han, Min-Kyu, Heier, Jeffrey, Hershberger, Vrinda, Higgins, Patrick, Hsu, Jason, Ip, Michael, Jablon, Eric, Jewart, Brian, John, Vishak, Jonisch, Jonathan, Joondeph, Brian, Kay, Christine, Khanani, Arshad, Kokame, Gregg T., Kwun, Robert, Lai, Michael, Lally, David, Laud, Ketan, Lavina, Adrian, Lee, Michael, Lin, Phoebe, Lin, Haijiang, Manoharan, Niranjan, Marcus, Dennis, Martidis, Adam, McCabe, Frank, Nielsen, Jared, Osher, James, Palmer, James, Patel, Sunil, Pearlman, Joel, Perkins, Stephen, Pirouz, Ashkan, Qureshi, Jawad, Randolph, John, Piri, Niloofar, Rosenfeld, Phillip, Saperstein, David, Scartozzi, Richard, Schwartz, Steven, Sharma, Ashish, Sharma, Atul, Sheth, Veeral, Singer, Michael, Spinak, David, Suan, Eric, Tabandeh, Homayoun, Tabassian, Ali, Uchiyama, Eduardo, Varenhorst, Michael, Wagner, Alan, Warrow, David, Wells, III, John, Wong, Robert, Wong, Keye, Wykoff, Charles, Xavier, Samantha, Ysasaga, Edward·2023·The Lancet

Abstract

BACKGROUND Geographic atrophy is an advanced form of dry age-related macular degeneration that can lead to irreversible vision loss and high burden of disease. We aimed to assess efficacy and safety of avacincaptad pegol 2 mg in reducing geographic atrophy lesion growth. METHODS GATHER2 is a randomised, double-masked, sham-controlled, 24-month, phase 3 trial across 205 retina clinics, research hospitals, and academic institutions globally. To be eligible, patients had to be aged 50 years or older with non-centrepoint-involving geographic atrophy and best corrected visual acuity between 20/25 and 20/320 in the study eye. Eligible patients were randomly assigned (1:1) to monthly avacincaptad pegol 2 mg administered as a 100 μL intravitreal injection or sham for the first 12 months. Randomisation was performed using an interactive response technology system with stratification by factors known to be of prognostic importance in age-related macular degeneration. Patients, investigators, study centre staff, sponsor personnel, and data analysts were masked to treatment allocation. The primary endpoint was geographic atrophy lesion size measured by fundus autofluorescence at baseline, month 6, and month 12. Efficacy and safety analyses were done in the modified intention-to-treat and safety populations, respectively. This trial is registered with ClinicalTrials.gov, NCT04435366. FINDINGS Between June 22, 2020, and July 23, 2021, 1422 patients were screened for eligibility, of whom 448 were enrolled and randomly assigned to avacincaptad pegol 2 mg (n=225) or sham (n=223). One patient in the sham group did not receive study treatment and was excluded from analyses. There were 154 (68%) female patients and 71 (32%) male patients in the avacincaptad pegol 2 mg group, and 156 (70%) female patients and 66 (30%) male patients in the sham group. From baseline to month 12, the mean rate of square-root-transformed geographic atrophy area growth was 0·336 mm/year (SE 0·032) with avacincaptad pegol 2 mg and 0·392 mm/year (0·033) with sham, a difference in growth of 0·056 mm/year (95% CI 0·016-0·096; p=0·0064), representing a 14% difference between the avacincaptad pegol 2 mg group and the sham group. Ocular treatment-emergent adverse events in the study eye occurred in 110 (49%) patients in the avacincaptad pegol 2 mg group and 83 (37%) in the sham group. There were no endophthalmitis, intraocular inflammation, or ischaemic optic neuropathy events over 12 months. To month 12, macular neovascularisation in the study eye occurred in 15 (7%) patients in the avacincaptad pegol 2 mg group and nine (4%) in the sham group, with exudative macular neovascularisation occurring in 11 (5%) in the avacincaptad pegol 2 mg group and seven (3%) in the sham group. INTERPRETATION Monthly avacincaptad pegol 2 mg was well tolerated and showed significantly slower geographic atrophy growth over 12 months than sham treatment, suggesting that avacincaptad pegol might slow disease progression and potentially change the trajectory of disease for patients with geographic atrophy. FUNDING Iveric Bio, An Astellas Company.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)01583-0

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 366

Metadata

Authors
Khanani, A. M., Patel, S. S., Staurenghi, G., Tadayoni, R., Danzig, C. J., Eichenbaum, D. A., Hsu, J., Wykoff, C. C., Heier, J. S., Lally, D. R., Monés, J., Nielsen, J. S., Sheth, V. S., Kaiser, P. K., Clark, J., Zhu, L., Patel, H., Tang, J., Desai, D., Jaffe, G. J., Alezzandrini, A., Francone, A. A., Bafalluy, J., Bainttein, S., Luna Pinto, J., Saravia, M., Vidosevich, M., Zeolite, C., Furno Sola, F., Chang, A., Cornish, E. E. G., Nguyen, T., Findl, O., Haas, A., Kralinger, M., Sacu, S., Postelmans, L. D., Farah, M., Maia, M., Nehemy, M., Ali, F., Brent, M., Dollin, M., Gonder, J., Kherani, A., Merkur, A., Tuli, R., Lopera, M. M., Rodriguez, F., Bradvica, M., Ernest, J., Kalijurand, K., Noor, K., Cohen, Y., Creuzot-Garcher, C., De Bats, F., Devin, F., Français-Maury, C., Kodjikian, L., Korobelnik, J. F., Le Mer, Y., Quaranta El Maftouhi, M., Razavi, S., Souied, E., Tadayoni, R., Weber, M., Eter, N., Feltgen, N., Grisanti, S., Walter, P., Liegl, R., Lorenz, K., Spital, G., Priglinger, S., Spitzer, M., Volker, M., Krohne, T., Jochmann, C., Lohmann, C. P., Framme, C., Kerenyi, A., Papp, A., Seres, A., Toth-Molnar, E., Tsorbatzoglou, A., Vajas, A., Varsanyi, B., Vogt, G., Bar, A., Eting, E., Hauser, D., Levy, J., Mathalone, N., Morori-Katz, H., Rosenblatt, I., Soudry-Zayit, S., Trivizky, O., Bandello, F., Ciardella, A. P., Figus, M., Giansanti, F., Lanzetta, P., Mariotti, C., Mastropasqua, L., Midena, E., Parmeggiani, F., Ricci, F., Simonelli, F., Staurenghi, G., Viola, F., Varano, M., Laganovska, G., Cisiecki, S., Jedrzejewski, W., Kaluzny, J., Misiuk-Hojło, M., Abengoechea, S., Iribarren, J. A., Ascaso, F. J., Cubero, J. M., Gallego-Pinazo, R., Gomez-Ulla De Irazazabal, F., Mestre, I. J., Mones I Carilla, J. M., Montero Moreno, J., María Ruiz Moreno, J., Sararols Ramsay, L., Garcia Layana, A., Downey, L., Abraham, P., Alfaro, D. V., Bagheri, N., Barbazetto, I., Benevento, J., Bernstein, P., Bertolucci, G., Bhavsar, A., Bridges, W., Brooks, Jr., Brown, J., Brucker, A., Calvo, C. M., Capone, A., Carlson, J., Chan, C., Chang, E., Chan-Kai, B., Chaudhry, N., Chen, S., Csaky, K., Cummings, H., Danzig, C., Dessouki, A., Dyer, D., Eaton, A., Eichenbaum, D., Faber, D., Feldman, R., Finnen, N., Freeman, W., Frenkel, R., Gonzales, C., Gonzalez, V., Gross, J., Gupta, S., Hall, E., Han, M.-K., Heier, J., Hershberger, V., Higgins, P., Hsu, J., Ip, M., Jablon, E., Jewart, B., John, V., Jonisch, J., Joondeph, B., Kay, C., Khanani, A., Kokame, G. T., Kwun, R., Lai, M., Lally, D., Laud, K., Lavina, A., Lee, M., Lin, P., Lin, H., Manoharan, N., Marcus, D., Martidis, A., McCabe, F., Nielsen, J., Osher, J., Palmer, J., Patel, S., Pearlman, J., Perkins, S., Pirouz, A., Qureshi, J., Randolph, J., Piri, N., Rosenfeld, P., Saperstein, D., Scartozzi, R., Schwartz, S., Sharma, A., Sharma, A., Sheth, V., Singer, M., Spinak, D., Suan, E., Tabandeh, H., Tabassian, A., Uchiyama, E., Varenhorst, M., Wagner, A., Warrow, D., Wells, III, Wong, R., Wong, K., Wykoff, C., Xavier, S., & Ysasaga, E.
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-10
Volume
402
Issue
10411
Pages
1449-1458
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4386552811
Cited by
366
References
25
FWCI
75.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01583-0
The paper
Khanani, A. M., Patel, S. S., Staurenghi, G., Tadayoni, R., Danzig, C. J., Eichenbaum, D. A., Hsu, J., Wykoff, C. C., Heier, J. S., Lally, D. R., Monés, J., Nielsen, J. S., Sheth, V. S., Kaiser, P. K., Clark, J., Zhu, L., Patel, H., Tang, J., Desai, D., . . . Ysasaga, E. (2023). Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)01583-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.